Groundbreaking New Treatments for Depression and PTSD Taking Market Share from the $380 Billion Mental Health Market by Improving Care and Relief for Veterans and Global Patient Communities.
Who is Apex?
How Big is the Problem?
THE SOLUTION: MASSIVE OPPORTUNITY WITH PSILOCYBIN
WHY APEX AND WHY APEX NOW
HOW BIG IS THE POTENTIAL MARKET?
WHAT IS THE FINANCIAL OPPORTUNITY FOR APEX LABS?
Taking even a 1% market share of the mental health market puts APEX at nearly $4B in revenue.
APEX IN THE NEWS
THE APEX STORY
Tyler PowellCo-Founder, Chief Executive Officer and Director
Decades of experience as an entrepreneur, passionate about innovating in pharmaceuticals, supporting in-need populations and revolutionizing their standard of mental health care.
Arron VictoryCo-Founder, Chief Strategy Officer and Director
Ambassador for Wounded Warriors Canada & Advisor to the Chronic Pain Centre of Excellence & Heroic Hearts Project with patient & operational
Dr. Orion LekosChief Science Officer and Director
Ex-Tilray scientist specialized in IP portfolio and drug development innovation. Led global clinical trials while being instrumental in the design of extraction and formulation for a top three global cannabis company.
Dr. Peter TomlinsonCo-Founder and Chief Technical Officer
Prominent industry leader specializing in clinical trials & pharmaceutical commercialization partnering with leading companies such as Tilray, Aegera, Purgenesis, Ultragenyx, Sharp & Taro
Dr. Mark JohnstonChief Medical Officer
Experienced psychiatrist practicing for over 15 years while running a private Veteran-focused clinic network and involved in numerous clinical trials.
Sam IsaacChief Financial Officer
Brings 15 years of experience in private equity, international capital markets and start ups. Specializes in heavily regulated sectors cannabis R&D, tech & energy.
Greg RutherfordChief Commercial Officer
Senior global pharma commercialization & marketing expert optimizing drug product lifecycles and commercial strategy with past roles at Johnson & Johnson, Roche, GSK, Lilly and McKesson
Dr. Enrique CarrazanaIndependent Director
Harvard-trained Neurologist with a career spanning over 25 years in drug development and the pharmaceutical industry
Tom McGaughIndependent Director and Audit Chair
Provides nearly two decades of financial accounting excellence & experience supporting start-ups, small businesses & publicly traded companies across the globe.
Jim PakulisIndependent Director
Vast executive corporate experience as CEO & Director of numerous successful public & private companies across North America raising millions in conjunction.
The purpose of this raise is to launch three clinical trials leading to a Q1/Q2 2024 IPO on the NYSE or NASDAQ.
Once the financing is closed, electronic verification of share issuances will be sent from DLA Piper law firm.
What is your exit plan? This is a build to acquire model. Post positive read out data from our phase 2b clinical trials, Apex will have big pharma looking to acquire.
*** Need to verify ***
Apex is wrapping up its two year PCAOB audit in September with an aim of filing a S1/F1 go public registration statement by the end of the year. This would align with a listing date in H1 2024.
If an investor met the required qualifications to participate in an Apex clinical trial or SAP application, we would be open to incentivizing that shareholder/patient.
Yes, two data rooms. One created by DLA Piper with all supporting legal and a second more focused on VC investors.
Verified accredited investor